These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 20472603)
1. Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan. Sugiura S; Nakanishi H; Asano M; Hashida T; Tanimura M; Hama T; Nabeshima T J Oncol Pharm Pract; 2011 Mar; 17(1):20-8. PubMed ID: 20472603 [TBL] [Abstract][Full Text] [Related]
2. Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. Sugiura S; Asano M; Kinoshita K; Tanimura M; Nabeshima T J Oncol Pharm Pract; 2011 Mar; 17(1):14-9. PubMed ID: 20179165 [TBL] [Abstract][Full Text] [Related]
3. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Acampora A; Castiglia L; Miraglia N; Pieri M; Soave C; Liotti F; Sannolo N Ann Occup Hyg; 2005 Oct; 49(7):611-8. PubMed ID: 15964876 [TBL] [Abstract][Full Text] [Related]
4. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Minoia C; Turci R; Sottani C; Schiavi A; Perbellini L; Angeleri S; Draicchio F; Apostoli P Rapid Commun Mass Spectrom; 1998; 12(20):1485-93. PubMed ID: 9796535 [TBL] [Abstract][Full Text] [Related]
5. Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Yoshida J; Koda S; Nishida S; Yoshida T; Miyajima K; Kumagai S J Oncol Pharm Pract; 2011 Mar; 17(1):29-38. PubMed ID: 20699333 [TBL] [Abstract][Full Text] [Related]
6. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. Sessink PJ; Leclercq GM; Wouters DM; Halbardier L; Hammad C; Kassoul N J Oncol Pharm Pract; 2015 Apr; 21(2):118-27. PubMed ID: 24567041 [TBL] [Abstract][Full Text] [Related]
7. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. Hedmer M; Jönsson BA; Nygren O J Environ Monit; 2004 Dec; 6(12):979-84. PubMed ID: 15568047 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of occupational exposure to cyclophosphamide in nine hospitals of Peru]. Rosales-Rimache JA Rev Peru Med Exp Salud Publica; 2013; 30(4):590-4. PubMed ID: 24448934 [TBL] [Abstract][Full Text] [Related]
9. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Wick C; Slawson MH; Jorgenson JA; Tyler LS Am J Health Syst Pharm; 2003 Nov; 60(22):2314-20. PubMed ID: 14652980 [TBL] [Abstract][Full Text] [Related]
10. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Fransman W; Peelen S; Hilhorst S; Roeleveld N; Heederik D; Kromhout H Ann Occup Hyg; 2007 Apr; 51(3):231-9. PubMed ID: 17337460 [TBL] [Abstract][Full Text] [Related]
11. Verification of surface contamination of Japanese cyclophosphamide vials and an example of exposure by handling. Hama K; Fukushima K; Hirabatake M; Hashida T; Kataoka K J Oncol Pharm Pract; 2012 Jun; 18(2):201-6. PubMed ID: 21947739 [TBL] [Abstract][Full Text] [Related]
12. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study. Fransman W; Vermeulen R; Kromhout H Ann Occup Hyg; 2004 Apr; 48(3):237-44. PubMed ID: 15059800 [TBL] [Abstract][Full Text] [Related]
13. Occupational exposure to cyclophosphamide in nurses at a single center. Ramphal R; Bains T; Vaillancourt R; Osmond MH; Barrowman N J Occup Environ Med; 2014 Mar; 56(3):304-12. PubMed ID: 24481248 [TBL] [Abstract][Full Text] [Related]
14. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696 [TBL] [Abstract][Full Text] [Related]
15. [Analysis of cyclophosphamide in the urine of antineoplastic drugs handlers]. Favier B; Gilles L; Desage M; Latour JF Bull Cancer; 2003 Oct; 90(10):905-9. PubMed ID: 14706919 [TBL] [Abstract][Full Text] [Related]
16. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: A 2016 follow-up study. Roland C; Caron N; Bussières JF J Occup Environ Hyg; 2017 Aug; 14(8):661-669. PubMed ID: 28574754 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department. Castiglia L; Miraglia N; Pieri M; Simonelli A; Basilicata P; Genovese G; Guadagni R; Acampora A; Sannolo N; Scafarto MV J Occup Health; 2008; 50(1):48-56. PubMed ID: 18285644 [TBL] [Abstract][Full Text] [Related]
18. Development of a closed drug preparation method for oral anticancer drugs. Wakui N; Ookubo T; Iwasaki Y; Ito R; Saito K; Nakazawa H J Oncol Pharm Pract; 2013 Dec; 19(4):315-20. PubMed ID: 23292970 [TBL] [Abstract][Full Text] [Related]
19. Utilization of the solid sorbent media in monitoring of airborne cyclophosphamide concentrations and the implications for occupational hygiene. Odraska P; Dolezalova L; Piler P; Oravec M; Blaha L J Environ Monit; 2011 May; 13(5):1480-7. PubMed ID: 21468422 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of environmental contaminations and occupational exposures involved in preparation of chemotherapeutic drugs. Maeda S; Miyawaki K; Matsumoto S; Oishi M; Miwa Y; Kurokawa N Yakugaku Zasshi; 2010 Jun; 130(6):903-10. PubMed ID: 20519870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]